Correspondingly, the IL‐6 receptor blockade, named tocilizumab, has been approved for use in patients with COVID‐19 who exhibit cytokine release syndrome [5]; the trial of using IL‐1 blockade (anakinra) in sepsis has been applied in clinical treatment as well [61]. Here, IL1B is linked to COVID-19.